Patents Represented by Attorney Melya J. Hughes
  • Patent number: 5965543
    Abstract: Recombinant polynucleotides have expression control sequences that have a senescence responsive element and a minimal promoter, and which are operatively linked to a heterologous nucleotide sequence. The molecules are useful for achieving high levels of expression of genes in senescent cells. Methods of inhibiting expression of genes in senescent cells also are provided.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: October 12, 1999
    Assignee: Geron Corporation
    Inventors: Judith Campisi, Alessandro Testori
  • Patent number: 5891639
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: April 6, 1999
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5863726
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: January 26, 1999
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5840490
    Abstract: Methods for detecting hematologic and colorectal malignancies are provided comprising: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the presence of telomerase activity with the presence of cancer cells. A method for staging leukemia is also provided comprising analyzing a blood or bone marrow sample for telomerase activity, correlating the activity with a standard level of telomerase activity, and correlating a low telomerase activity with early stage leukemia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: McMaster University
    Inventors: Silvia Bacchetti, Christopher M. Counter, Brian Leber, Calvin Bruce Harley
  • Patent number: 5837453
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol involving telomerase substrate and primer extension steps. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose the course of disease progression in a patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5804380
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: September 8, 1998
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5705342
    Abstract: The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: James R. Bischoff, Maria Jose Fernandez-Sarabia
  • Patent number: 5693474
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright
  • Patent number: 5639613
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 17, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright